Stonehage Fleming Financial Services Holdings Ltd lifted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 18.5% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 8,975 shares of the company’s stock after buying an additional 1,402 shares during the quarter. Stonehage Fleming Financial Services Holdings Ltd’s holdings in Johnson & Johnson were worth $1,261,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds and other institutional investors also recently made changes to their positions in JNJ. Sofos Investments Inc. grew its holdings in shares of Johnson & Johnson by 172.0% during the first quarter. Sofos Investments Inc. now owns 1,148 shares of the company’s stock valued at $33,000 after buying an additional 726 shares during the last quarter. Altshuler Shaham Ltd bought a new position in Johnson & Johnson during the first quarter valued at approximately $35,000. Lake Point Wealth Management lifted its position in Johnson & Johnson by 144.4% during the first quarter. Lake Point Wealth Management now owns 286 shares of the company’s stock valued at $38,000 after purchasing an additional 169 shares during the period. Islay Capital Management LLC bought a new position in Johnson & Johnson during the second quarter valued at approximately $42,000. Finally, Lion Street Advisors LLC bought a new position in Johnson & Johnson during the first quarter valued at approximately $45,000. Institutional investors own 67.44% of the company’s stock.
In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 16,115 shares of Johnson & Johnson stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $153.52, for a total value of $2,473,974.80. Following the completion of the transaction, the executive vice president now directly owns 66,658 shares of the company’s stock, valued at approximately $10,233,336.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Ashley Mcevoy sold 29,000 shares of Johnson & Johnson stock in a transaction on Tuesday, July 28th. The stock was sold at an average price of $147.47, for a total transaction of $4,276,630.00. Following the completion of the transaction, the executive vice president now directly owns 21,682 shares of the company’s stock, valued at $3,197,444.54. The disclosure for this sale can be found here. Company insiders own 0.27% of the company’s stock.
Shares of JNJ stock traded up $0.50 on Tuesday, hitting $148.85. 260,114 shares of the stock traded hands, compared to its average volume of 8,504,898. The firm has a market cap of $390.58 billion, a price-to-earnings ratio of 21.77, a PEG ratio of 3.27 and a beta of 0.68. Johnson & Johnson has a 52 week low of $109.16 and a 52 week high of $157.00. The firm has a 50 day simple moving average of $149.29 and a two-hundred day simple moving average of $144.17. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.25 and a quick ratio of 0.99.
Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Thursday, July 16th. The company reported $1.67 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.50 by $0.17. The company had revenue of $18.34 billion during the quarter, compared to analysts’ expectations of $17.73 billion. Johnson & Johnson had a net margin of 22.69% and a return on equity of 35.21%. Johnson & Johnson’s quarterly revenue was down 10.8% on a year-over-year basis. During the same period last year, the company posted $2.58 earnings per share. Sell-side analysts forecast that Johnson & Johnson will post 7.85 EPS for the current year.
The business also recently announced a quarterly dividend, which was paid on Tuesday, September 8th. Investors of record on Tuesday, August 25th were paid a dividend of $1.01 per share. The ex-dividend date was Monday, August 24th. This represents a $4.04 annualized dividend and a yield of 2.71%. Johnson & Johnson’s payout ratio is 46.54%.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Featured Article: What defines an oversold asset?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.